$6.26
3.22%
Nasdaq, Apr 21, 08:18 pm CET
ISIN
US2825591033
Symbol
ETNB
Sector
Industry

89bio Inc Stock price

$6.06
-2.64 30.34% 1M
-2.15 26.19% 6M
-1.76 22.51% YTD
-3.10 33.84% 1Y
+3.18 110.42% 3Y
-16.37 72.98% 5Y
-14.74 70.87% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.17 2.89%
ISIN
US2825591033
Symbol
ETNB
Sector
Industry

Key metrics

Market capitalization $884.66m
Enterprise Value $482.25m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.81
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-384.66m
Free Cash Flow (TTM) Free Cash Flow $-367.84m
Cash position $439.96m
EPS (TTM) EPS $-3.43
P/E forward negative
Short interest 12.44%
Show more

Is 89bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

89bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a 89bio Inc forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a 89bio Inc forecast:

Buy
82%
Hold
18%

Financial data from 89bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
69% 69%
-
-0.04 -0.04
69% 69%
-
- Selling and Administrative Expenses 40 40
38% 38%
-
- Research and Development Expense 345 345
182% 182%
-
-385 -385
155% 155%
-
- Depreciation and Amortization 0.04 0.04
69% 69%
-
EBIT (Operating Income) EBIT -385 -385
154% 154%
-
Net Profit -367 -367
158% 158%
-

In millions USD.

Don't miss a Thing! We will send you all news about 89bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

89bio Inc Stock News

Positive
Seeking Alpha
3 days ago
Initiate Buy rating for 89bio, Inc. due to promising lead candidate pegozafermin targeting MASH and SHTG with encouraging Phase 2 data. Pegozafermin may have faster fibrosis improvement and better safety profile compared to competitors, potentially capturing significant market share in MASH and SHTG. Financially, 89bio has a solid cash position but may need to raise capital by mid to late 2026,...
Neutral
GlobeNewsWire
about 2 months ago
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the Leerink Partners Global Health...
Neutral
GlobeNewsWire
about 2 months ago
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – –The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 v...
More 89bio Inc News

Company Profile

89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.

Head office United States
CEO Rohan Palekar
Employees 93
Founded 2018
Website www.89bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today